Clinical Trial Update: An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pevonedistat plus azacitidine versus azacitidine alone in higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia Myeloid Acute
• Leukemia Myelomonocytic Chronic
• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Pevonedistat (pevonedistat)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2020-09-23